Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer

Cell Cycle

Volumn 13, Issue 2, 2014, Pages 199-207

  Aird, Katherine M ^a   Li, Hua ^a   Xin, Frances ^b   Konstantinopoulos, Panagiotis A ^c   Zhang, Rugang ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell proliferation; Cellular senescence; DNA damage response; Epithelial ovarian cancer; Ribonucleotide reductase M2 (RRM2)

Indexed keywords

HISTONE H2AX; KI 67 ANTIGEN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; UNCLASSIFIED DRUG; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL AGING; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; ENDOMETRIUM; EPITHELIUM; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENESCENCE; UPREGULATION; UTERINE TUBE; UTERINE TUBE MUCOSA; CANCER GRADING; CANCER STAGING; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; EPITHELIUM; FALLOPIAN TUBES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SURVIVAL RATE;

EID: 84892585489     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26953     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Arulkumaran S, Regan L, Farquharson DIM. Obstetrics and gynaecology. Oxford: Oxford University Press, 2011
3. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008; 18:538-48; PMID:18427574; http://dx.doi.org/10.1038/cr. 2008.52 (Pubitemid 351630950)
4. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-8; PMID:15111296; http://dx.doi.org/10.1016/S0002-9440(10)63708-X (Pubitemid 38529752)
5. Vaughan S, Coward JI, Bast RC Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719-25; PMID:21941283; http://dx.doi.org/10.1038/nrc3144
6. Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 2006; 75: 681-706; PMID:16756507; http://dx.doi.org/10.1146/annurev.biochem.75. 103004.142443 (Pubitemid 44118048)
7. Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 1985; 260: 9114-6; PMID:3894352 (Pubitemid 15249885)
8. Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010; 1805: 141-52; PMID:20122995
9. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006; 6: 409-31; PMID:16918309; http://dx.doi.org/10.2174/156800906777723949 (Pubitemid 44033390)
10. Lin ZP, Belcourt MF, Cory JG, Sartorelli AC. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem 2004; 279: 27030-8; PMID:15096505; http://dx.doi.org/10.1074/jbc.M402056200 (Pubitemid 38812539)
11. Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, et al. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond) 2013; 124: 567-78; PMID:23113760; http://dx.doi.org/10.1042/CS20120240
12. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010; 12: 807-17; PMID:20927319
13. Jones DT, Lechertier T, Mitter R, Herbert JM, Bicknell R, Jones JL, Li JL, Buffa F, Harris AL, Hodivala-Dilke K. Gene expression analysis in human breast cancer associated blood vessels. PLoS One 2012; 7:e44294; PMID:23056178; http://dx.doi.org/10.1371/journal.pone.0044294
14. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine- 2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004; 22: 1553-63; PMID:15117978; http://dx.doi.org/10.1200/JCO.2004.07.158 (Pubitemid 41079792)
15. Chao J, Synold TW, Morgan RJ Jr., Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, et al. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol 2012; 69: 835-43; PMID:22105720; http://dx.doi.org/10.1007/s00280-011-1779-5
16. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-40; PMID:17667954; http://dx.doi.org/10.1038/nrm2233 (Pubitemid 47312822)
17. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92:9363-7; PMID:7568133; http://dx.doi.org/10.1073/pnas.92.20.9363
18. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120:681-93; PMID:20197621; http://dx.doi.org/10.1172/JCI40535
19. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-5; PMID:17251932; http://dx.doi.org/10.1038/nature05541 (Pubitemid 46232887)
20. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-60; PMID:17251933; http://dx.doi.org/10.1038/nature05529 (Pubitemid 46232886)
21. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503-11; PMID:21701512; http://dx.doi.org/10.1038/nrc3057
22. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102: 1536-46; PMID:20858887; http://dx.doi.org/10.1093/jnci/djq364
23. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, et al. Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. Cell Rep 2013.
24. Mannava S, Moparthy KC, Wheeler LJ, Leonova KI, Wawrzyniak JA, Bianchi-Smiraglia A, Berman AE, Flanagan S, Shewach DS, Zeitouni NC, et al. Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. Aging (Albany NY) 2012; 4: 917-22; PMID:23249808
25. Mannava S, Moparthy KC, Wheeler LJ, Natarajan V, Zucker SN, Fink EE, Im M, Flanagan S, Burhans WC, Zeitouni NC, et al. Depletion of deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence. Am J Pathol 2013; 182: 142-51; PMID:23245831; http://dx.doi.org/10. 1016/j.ajpath.2012.09.011
26. Darzynkiewicz Z. Perturbation of nucleotide metabolism - the driving force of oncogene-induced senescence. Oncotarget 2013; 4: 649-50; PMID:23660114
27. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-43; PMID:20154587; http://dx.doi.org/10.1097/PAS.0b013e3181cf3d79
28. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26:5284-93; PMID:18854563; http://dx.doi.org/10.1200/JCO.2008.18.1107
29. McCarty KS Jr., Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, et al. Use of a monoclonal antiestrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46(Suppl):4244s-8s; PMID:3524805 (Pubitemid 16041242)
30. McCarty KS Jr., Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-21; PMID:3893381 (Pubitemid 16237466)
31. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006; 66: 1354-62; PMID:16452189; http://dx.doi.org/10.1158/0008-5472.CAN-05-3694 (Pubitemid 43259914)
32. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al.; Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-208; PMID:18698038; http://dx.doi.org/10.1158/1078-0432.CCR-08-0196
33. Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, Sartorelli AC. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 1994; 48: 335-44; PMID:8053929; http://dx.doi.org/10.1016/0006- 2952(94)90105-8
34. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999; 39: 3-12; PMID:10470363; http://dx.doi.org/10.1016/S0065-2571(98)00017-X
35. Wang LM, Lu FF, Zhang SY, Yao RY, Xing XM, Wei ZM. Overexpression of catalytic subunit M2 in patients with ovarian cancer. Chin Med J (Engl) 2012; 125: 2151-6; PMID:22884145
36. Zhang M, Wang J, Yao R, Wang L. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer. Int J Gynecol Cancer 2013; 23: 659-66; PMID:23466567; http://dx.doi.org/10.1097/IGC.0b013e318287e2b3
37. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res 2011; 71: 6184-94; PMID:21816908; http://dx.doi.org/10.1158/0008-5472.CAN-11-1341
38. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008; 27: 2801-9; PMID:18193093; http://dx.doi.org/10.1038/sj.onc.1210950 (Pubitemid 351620451)
39. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24:2463-79; PMID:21078816; http://dx.doi.org/10.1101/gad.1971610
40. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992; 52: 4196-9; PMID:1638534
41. Watson JE, Gabra H, Taylor KJ, Rabiasz GJ, Morrison H, Perry P, Smyth JF, Porteous DJ. Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res 1999; 9: 226-33; PMID:10077528 (Pubitemid 29168185)
42. Halicka HD, Zhao H, Li J, Lee YS, Hsieh TC, Wu JM, Darzynkiewicz Z. Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY) 2012; 4:952-65; PMID:23363784
43. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79; PMID:14576837; http://dx.doi.org/10. 1038/sj.onc.1206933
44. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010; 7: 508-19; PMID:20700108; http://dx.doi.org/10.1038/nrclinonc.2010.116
45. Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010; 8: 1610-8; PMID:21115743; http://dx.doi.org/10.1158/1541-7786.MCR-10-0398
46. Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams PD. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 2007; 27: 183-96; PMID:17643369; http://dx.doi.org/10.1016/j.molcel.2007.05.034 (Pubitemid 47058300)
47. Wainstock DH. A decade of Developmental Cell. Dev Cell 2011; 21:1; PMID:21763596; http://dx.doi.org/10.1016/j.devcel.2011.07.002
48. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005; 8: 19-30; PMID:15621527; http://dx.doi.org/10.1016/j.devcel.2004.10.019 (Pubitemid 40058002)
49. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007; 27: 2343-58; PMID:17242207; http://dx.doi.org/10.1128/MCB.02019-06 (Pubitemid 46418486)
50. Zhang R, Liu ST, Chen W, Bonner M, Pehrson J, Yen TJ, Adams PD. HP1 proteins are essential for a dynamic nuclear response that rescues the function of perturbed heterochromatin in primary human cells. Mol Cell Biol 2007; 27: 949-62; PMID:17101789; http://dx.doi.org/10.1128/MCB.01639-06 (Pubitemid 46178114)